Monday, October 11, 2021 5:24:25 PM
Thank you , but don’t bother yourself , no need to explain anymore to me , I understand fine medical studies..
I know how studies are done , I did some myself .
One should read the approved by FDA protocol. We not talking about some subgroups , we talking about 2 groups , specify and approved by FDA before study started,
So it is not important how many will try to confuse this study.
Picture is really simple..
I also know what companies need to do , and I know that companies need to do what is approved for them by FDA in the protocol ..
And I know other drugs results by their protocols , and I know our CD12 ..
In our Group B it showed definitely saving lives , above ALL other approved drugs in this pandemic …
So one will hope that dr Fauci and FDA will be happy and approve it very fast .,
But no , as an answer FDA posted a hit letter , at only working to save lives drug .
To what I know , only second hit letter on any company in the history of FDA .,
Letter who no one signed , Dr Woodcock emailed to someone she didn’t know or approved it .
And it is hard to find any information so far..
But it look that it might be discover who was behind it in some near future .,
And as Americans dying daily the best drug for covid , and the only one without one serious side effect is not approve .
After what happened to my son I am on a mission , I want all sick to be able to ask for Leronlimab , and not when they dying to get RTT , much much sooner without any problems , sickness is problem enough for a patient , and the family...
Is that to much to ask in our great USA .,
All imo
I know how studies are done , I did some myself .
One should read the approved by FDA protocol. We not talking about some subgroups , we talking about 2 groups , specify and approved by FDA before study started,
So it is not important how many will try to confuse this study.
Picture is really simple..
I also know what companies need to do , and I know that companies need to do what is approved for them by FDA in the protocol ..
And I know other drugs results by their protocols , and I know our CD12 ..
In our Group B it showed definitely saving lives , above ALL other approved drugs in this pandemic …
So one will hope that dr Fauci and FDA will be happy and approve it very fast .,
But no , as an answer FDA posted a hit letter , at only working to save lives drug .
To what I know , only second hit letter on any company in the history of FDA .,
Letter who no one signed , Dr Woodcock emailed to someone she didn’t know or approved it .
And it is hard to find any information so far..
But it look that it might be discover who was behind it in some near future .,
And as Americans dying daily the best drug for covid , and the only one without one serious side effect is not approve .
After what happened to my son I am on a mission , I want all sick to be able to ask for Leronlimab , and not when they dying to get RTT , much much sooner without any problems , sickness is problem enough for a patient , and the family...
Is that to much to ask in our great USA .,
All imo
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
